S
Siew-leng Melinda Teng
Researcher at Genentech
Publications - 6
Citations - 2295
Siew-leng Melinda Teng is an academic researcher from Genentech. The author has contributed to research in topics: Bladder cancer & Myeloid. The author has an hindex of 5, co-authored 6 publications receiving 2051 citations.
Papers
More filters
Journal ArticleDOI
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles,Joseph Paul Eder,Gregg Fine,Fadi Braiteh,Yohann Loriot,Cristina Cruz,Joaquim Bellmunt,Howard A. Burris,Daniel P. Petrylak,Siew-leng Melinda Teng,Xiaodong Shen,Zachary Boyd,Priti S. Hegde,Daniel S. Chen,Nicholas J. Vogelzang +14 more
TL;DR: It is demonstrated that tumours expressing PD-L1-positive tumour-infiltrating immune cells had particularly high response rates, and patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy.
Journal ArticleDOI
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).
Thomas Powles,Nicholas J. Vogelzang,Gregg Fine,Joseph Paul Eder,Fadi Braiteh,Yohann Loriot,Cristina Cruz Zambrano,Joaquim Bellmunt,Howard A. Burris,Siew-leng Melinda Teng,Xiaodong Shen,Hartmut Koeppen,Priti S. Hegde,Daniel S. Chen,Daniel P. Petrylak +14 more
TL;DR: PD-L1 expression is prevalent in this disease and may protect cancer cells from immune-mediated degranulation, leading to a poor prognosis and limited treatment options.
Journal ArticleDOI
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).
Daniel P. Petrylak,Thomas Powles,Joaquim Bellmunt,Fadi Braiteh,Yohann Loriot,Cristina Cruz Zambrano,Howard A. Burris,Joseph Kim,Siew-leng Melinda Teng,Jean-Marie Bruey,Priti S. Hegde,Oyewale O. Abidoye,Nicholas J. Vogelzang +12 more
TL;DR: PD-L1 may contribute to immune escape in UBC, a disease of high mutational complexity and immunogenicity and MPDL3280A was designed to restore T cell–mediated antitumor activity by restoring PD-L 1 activity.
Journal ArticleDOI
Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study.
Joseph Kim,Joaquim Bellmunt,Thomas Powles,Yohann Loriot,Nicholas J. Vogelzang,Cristina Cruz Zambrano,Howard A. Burris,Siew-leng Melinda Teng,Xiaodong Shen,Jean-Marie Bruey,Zachary Boyd,Priti S. Hegde,Daniel P. Petrylak +12 more
TL;DR: MPDL3280A is a PD-L1-targeting antibody with an engineered Fc domain that disrupts PD- l1/PD-1 and PD- L1/B7.1 signaling that may inhibit immune-mediated antitumor responses in metastatic urothelial bladder cancer.
Journal ArticleDOI
Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer
Yuanyuan Xiao,Christina Rabe,Marcin Kowanetz,Thomas Powles,Nicholas J. Vogelzang,Daniel P. Petrylak,Yohann Loriot,Mitchell Denker,Rin Nakamura,Qun J Wu,Teiko Sumiyoshi,Zachary Boyd,Siew-leng Melinda Teng,Xiaodong Shen,Gregg Fine,Daniel S. Chen,Priti S. Hegde +16 more
TL;DR: In this article, gene expression analyses of metastatic urothelial bladder cancer (UBC) patients were conducted to interrogate the tumor immune microenvironment in PD-L1-positive tumors and to identify potential mechanisms associated with response or resistance to MPDL3280A.